source
- Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trialA phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese biotech to advance into the phase 3 part of the study.Fierce Biotech · 14d ago↗ source
- FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in HorsesThe FDA today issued an Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses (ivermectin oral solution) for the short-term prevention of New World screwworm (NWS) infestations (myiasi…fda press · 14d ago↗ source
- FDA acting chief walks back Makary's practice of policymaking through journalsThe FDA is continuing to rewind actions by former Commissioner Marty Makary, saying that two medical journal articles published over the last year did not constitute agency policy. The about-face f…